These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8808711)

  • 1. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.
    Yu D; Liu B; Tan M; Li J; Wang SS; Hung MC
    Oncogene; 1996 Sep; 13(6):1359-65. PubMed ID: 8808711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
    Tan M; Yao J; Yu D
    Cancer Res; 1997 Mar; 57(6):1199-205. PubMed ID: 9067293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
    Yu D; Liu B; Jing T; Sun D; Price JE; Singletary SE; Ibrahim N; Hortobagyi GN; Hung MC
    Oncogene; 1998 Apr; 16(16):2087-94. PubMed ID: 9572489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
    Ueno NT; Yu D; Hung MC
    Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
    J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
    Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.
    Yu D; Shi D; Scanlon M; Hung MC
    Cancer Res; 1993 Dec; 53(23):5784-90. PubMed ID: 7902209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
    Chen X; Yeung TK; Wang Z
    Biochem Biophys Res Commun; 2000 Nov; 277(3):757-63. PubMed ID: 11062025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
    Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
    Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.
    Yu D; Wang SS; Dulski KM; Tsai CM; Nicolson GL; Hung MC
    Cancer Res; 1994 Jun; 54(12):3260-6. PubMed ID: 7911396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered gene expression in drug-resistant human breast cancer cells.
    Wosikowski K; Schuurhuis D; Kops GJ; Saceda M; Bates SE
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2405-14. PubMed ID: 9815641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
    Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells.
    Kang KS; Sun W; Nomata K; Morita I; Cruz A; Liu CJ; Trosko JE; Chang CC
    Mol Carcinog; 1998 Apr; 21(4):225-33. PubMed ID: 9585252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous genetic chemoprotection of normal marrow cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model.
    Hanania EG; Deisseroth AB
    Clin Cancer Res; 1997 Feb; 3(2):281-6. PubMed ID: 9815684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
    Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
    Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Apoptotic effect of the combined treatment of engineered antibody with paclitaxel on BT474 cells].
    Yin HJ; Cheng LS; Duan JL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Mar; 23(3):260-3. PubMed ID: 17343796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux.
    Brouty-Boyé D; Kolonias D; Wu CJ; Savaraj N; Lampidis TJ
    Cancer Res; 1995 Apr; 55(8):1633-8. PubMed ID: 7712466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.